Inventiva, a clinical-stage biopharmaceutical company focused on oral therapies for metabolic dysfunction-associated steatohepatitis (MASH), disclosed preliminary financial results for 2025, revealing a strengthened balance sheet following recent capital markets activity. The company reported €99.3 million in cash and equivalents combined with €131.6 million in short-term deposits as of the reporting date. Revenue generation reached €4.5 million during the period, while operating cash consumption totaled €104.6 million.
The company's liquidity position was bolstered by a $172.5 million public offering in the United States and complementary structured financing arrangements completed during the year. These capital injections have extended Inventiva's cash runway substantially, with management estimating current liquidity will support operations through mid-Q1 2027 under baseline scenarios. The company noted an extended funding horizon extending to mid-Q3 2027 in scenarios where warrant tranches are fully exercised by investors.
These preliminary results underscore Inventiva's ability to fund its clinical development pipeline through key value inflection points. The biopharmaceutical company's cash position and extended runway provide operational flexibility as it advances its MASH therapeutic candidates through clinical stages.